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active treatment rather than a negative lack of treatment or,
as Professor Stjernsward puts it, 'a waste-paper basket alter-
native' runs throughout the text and unifies the whole. The
holistic and interdisciplinary nature of palliative care is
emphasised by comprehensive and well-written chapters on
ethical, cultural and spiritual issues and bereavement. The
section on rehabilitation is noteworthy in that it covers topics
as diverse as stoma management and music therapy as well
as incontrovertibly demonstrating that rehabilitation is an
intrinsic part of palliative medicine.
The importance of research in palliative care is a recurring
theme throughout the book, and a specific section is devoted
to this topic. Studies in this field are, however, relatively
sparse, and the reasons for this are acknowledged and duly
addressed. In particular, Calman and Hanks refer to the
widespread view that 'scientifically rigorous clinical research
is incompatible with the basic tenets of palliative care', and
they put forward cogent arguments to refute this. This sec-
tion of the book is extremely wide-ranging, and discussion is
not limited to research into pharmacological and non-
pharmacological symptom management as nursing, psycho-
logical and social issues are also well covered. The fact that
palliative care crosses the traditional barriers of discipline
and specialty is highlighted in the section on education and
training. The authors stress that all the members of any
hospital-based or domiciliary team caring for patients with
cancer, be they doctors, nurses, social workers, physio-
therapists or clergy, need at least a working knowledge of the
philosophy of palliative care and suggest that this subject
should become an integral part of the curriculum of all
student health care professionals.
Although multiauthorship can bring problems through
inevitable variability of both style and approach, these are
not very apparent and there is a uniformly high standard of
presentation throughout the book. Despite a degree of over-
lap between chapters there is surprisingly little repetition. The
textbook is well indexed and all of the chapters are more
than adequately referenced. In parts, the text is rather dry
and it is tempting to speculate that it could be lightened by
more case histories and illustrations.
The book concludes with a thought-provoking dissertation
on the global perpsective of palliative medicine. Each year
fifty million people die worldwide. At least 10% die of
malignant disease, and it is likely that this proportion, in
addition to the numbers dying from AIDS-related diseases,
will continue to increase. Given that even in resource-rich,
developed nations there is inadequate application of the
available knowledge on palliative care, it is perhaps not
surprising that globally this field of medicine is badly
neglected. To rectify this situation changes are necessary not
only in medical practice but also in political, socioeconomic,
social and ethical arenas. The World Health Organization
has designated palliative care a priority in its Global Cancer
Control Programme, and encouraging progress is already
being achieved.
The Oxford Textbook ofPalliative Medicine is a book both
to dip in to, at leisure and when faced with an urgent clinical
problem to solve, and to read systematically to gain a full
insight into this field. Whilst its publication undoubtedly
represents a coming of age of palliative medicine as a
specialty in its own right, it is equally obvious that this new
specialty must continue to evolve.
Carol L. Davis
Chemoradiation. An Integrated Approach to Cancer Treatment
Edited by M.J. John, M.S. Flam. S.S. Legha & T.L. Phillips,
Philadelphia: Lea & Febiger, 1993. 688 pp. £75.00.
This book sets out to put forward the rationale for and
history to date of integrating chemotherapy and radiation in
the management of cancer. The book is divided into five
sections, with a brief introduction, the biological principles
underlining combined modality therapy, a clinical section
covering 17 disease sites, a section on toxicity and an appen-
dix summarising current clinical trials addressing the issue.
The second section includes some basic information about
the mechanisms and action of both radiation and cytotoxic
drugs, but most attention is focused on their use as sole
modalities with little information about possible interactions.
The clinical chapters are comprehensive and give an excellent
overview of combined modality therapy in the individual
disease sites. The section on toxicity tends to reproduce some
of the information included in the clinical chapters. Overall,
this book may be useful as a reference source in a depart-
mental library but it is unlikely to be of everyday relevance
to the majority of oncology clinicians.
G.M. Duchesne
New Approaches in Cancer Pharmacology: Drug Design and
Development
Edited by P. Workman, Berlin: Springer-Verlag, 1992,
103 pp.
This European School of Oncology Monograph recounts the
deliberations of a Task Force set up to examine current
progress and to anticipate future trends in cancer drug dis-
covery and pharmacology. The underlying theme is the need
for more effective drugs and the exciting opportunities
offered by the present understanding of the discrete mole-
cular abberations ofmalignant cells which provide targets for
selective attack. The contributors are all acknowledged
experts in their fields and this short monograph is well
written, authoritative and readable.
The review on sequence- and gene-specific drugs by D'In-
calci, Broggini and Hartley concentrates on alkylating agents
and their reactions with DNA as the major biochemical
events underpinning their cytotoxicities. It has been known
for some time that DNA damage is attributable to single-
and double-strand breaks, inter- and intra-strand cross-links
and possibly to DNA-protein cross-links. The site most
frequently alkylated is guanine N7, with lesser reaction occur-
ring at guanine 06 and adenine N3. The authors review
methodology which now enables an understanding of how
DNA base sequences influence the sites of alkylation of
various clinically used alkylating agents. It is now clear that
many common bifunctional alkylating agents react preferen-
tially with guanine N7 in contiguous runs of guanines in the
major groove of DNA. The authors emphasise that these
studies are carried out with parent drug and purified DNA
and take no account of cellular metabolism. Minor groove
binders include mitomycin C and CC-1065.
Claude Helene discussed antisense and antigene oligo-
nucleotides and synthetic ribozymes. The major requirements
of antisense oligos are emphasised: nuclease stability; preser-
vation of RNAse H activity; good cell penetration. The
advantages and shortcomings of the various linker chemis-
tries and the properties of chimaeric molecules comprising
conventional phosphodiester linkers in association with
methyl phosphonate, phosphorothioate or phosphoramidate
units is reviewed. Other chemical manoeuvres, including
coupling of oligos to hydrophobic moieties to enhance trans-
port and attachment of alkylating residues, both to achieve
nuclease stability and to increase potency, are mentioned
also. A consistent theme is the high selectivity that can be
achieved with antisense oligonucleotides in their effects, for
example on parasitically or virally infected cells, as well as on
tumour cells carrying a single point mutation in the Ha-ras
oncogene, amplified c-myc or in CML cells, where the
bcr-abl translocation can be targeted. Oligonucleotide-
directed triple helix formation, where Hoogstein hydrogen
bonding permits the association of a third oligo strand with
the nuclear DNA, is described as an 'anti-gene' strategy. The
triple helix can be effectively stabilised by the attachment of a
'docking' intercalator molecule. It is envisaged that this
approach will interfere with the function of transcription
factors and restriction enzymes, thus disturbing differ-
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antisense approach offers the promise of high selectivity in
the therapeutic setting, though there remain substantial phar-
macological difficulties which must be overcome before
antisense molecules can be used successfully in vivo.
In 'Prospects for Biological and Gene Therapies', Sikora
and Guiterrez justifiably point to the failure ofchemotherapy
to make a major impact on the treatment of common malig-
nancies. The authors discuss genetic immunomodulation,
normal tissue protection, drug targeting and gene replace-
ment therapy as possible future strategies. It has become
clear that cytokines can significantly affect tumour growth,
despite host toxicity. It is suggested that vectoring of
cytokine-coding genes, enhancing the expression of MHC I
and II molecules and transfecting tumour-infiltrating lym-
phocytes with TNF may be viable means to enhance tumour
immunogenicity. In the context of normal tissue protection
the authors point to the successful use of the haematopoietic
colony-stimulating factors in restoring bone marrow function
after ablative therapy. They propose that enhancement of
these moieties in bone marrow cells by recombinant methods
prior to treatment may well result in increased tolerance to
conventional cytotoxic drugs. Virally directed enzyme pro-
drug therapy (VDEPT) envisages the selective genetic expres-
sion in tumours of an enzyme which will convert an inactive
prodrug to an active cytotoxic species within tumour cells.
Examples of the use of thymidine kinase to convert Ara-A
into cytotoxic ArA nucleotides and of cytosine deaminase to
activate 5-fluorocytosine to the antimetabolite 5-fluorouracil
are quoted. Against a background of substantial in vitro
evidence that restoration of normal morphology and pheno-
type can be achieved by appropriate recombinant man-
oeuvres, the authors suggest that tumour-suppressor genes,
notably Rb and p53, are viable candidates for 'gene replace-
ment therapy'. As with their VDEPT proposals they stress
the critical requirement for selective and efficient vector
delivery.
John Hickman reviews cell membranes and signal trans-
duction pathways as targets for medicinal chemistry. The
development of tyrosine kinase inhibitors is outlined, listing
the natural products quercetin and genestein and a series of
thiazolidine-diones. These compounds all compete with ATP
for binding and thus offer the promise of less selectivity than
erbstatin and the tyrphostins, which are non-competitive with
ATP but competitive with enzyme in EGF receptor protein
tyrosine kinase assays. Several tyrphostins possessing both
potency and selectivity for individual tyrosine kinases are
now available, and detailed in vivo data are keenly awaited.
Attention is drawn also to the SH2 regions involved in
coupling other signal transduction molecules to tyrosine
kinase autophosphorylation sites: it is suggested that these
src homology domains provide good targets for molecular
intervention. Also discussed is inhibition of second mes-
sengers, notably phosphatidylinositol 3' kinase is inhibited by
D-3-deoxy-3-azido-myoinositol and phospholipase C by ether
lipids, two ofwhich, ET-18-OME and SRI 62-834, are under-
going clinical evaluation. The author observes that since the
biochemical pathways involved in signal transduction are
linked to cell proliferation, medicinal chemists will be pro-
ducing a new generation of antimetabolites complementary
to those in present use.
The design of novel antiendocrine drugs is presented by
Michael Jarman. New anti-oestrogens are discussed in the
context of the facile metabolism of tamoxifen and its reten-
tion of partial agonist activity, which may contribute to the
emergence of tumour resistance. Several congeners are cur-
rently undergoing clinical study, including droloxifene,
teremefin, TAT-59 and idoxefine (CB7432). The last com-
pound has a substantially improved affinity for the oestrogen
receptor compared with the other compounds. Also in
clinical study is the 7-substituted oestradiol derivative,
ICI 182,780 which is devoid of agonist activity. Blockade of
oestrogen biosynthesis can be achieved with aminogluteth-
imide, though the side-effects of this drug (sedation and
corticosteroid depletion) have prompted the search for an
alternative. Several compounds of varying potency are under-
going clinical study, including rogletimide, CGS 16949A and
CGS 20267. Amongst the steroidal inhibitors are 4-hydroxy-
androstenedione and MDL 18962. Since ovarian and tes-
ticular steroid biosynthesis is under LHRH control following
its release from the hypothalamus, LHRH agonists have been
used, frequently in combination with an inhibitor of oestro-
gen or androgen biosynthesis, to ablate hormone levels. The
synthesis of new anti-androgens, specifically inhibitors of
17a-hydroxylase/C17,201yase, based upon the model compound
ketoconazole, is described. Cyclohexyl-4-pyridyl acetate is a
lead compound from a group of 4-pyridylacetic acid esters
which exhibit good binding affinities. Another important
target for anti-androgen drug design is testosterone 5a-
reductase, and modelling and structure-activity studies are
described. In his concluding discussion the author observes
that, in view of the plethora of highly potent and selective
aromatase inhibitors, the value of this target in breast cancer
chemotherapy will surely be established in the near future.
Paul Workman writes on the design of novel bioreductive
drugs, outlining the biology of hypoxia and its association
with both radio- and chemoresistance. The nitroimidazole
radiosensitisers are elaborated as a major strategy to circum-
vent radioresistance. The clinical limitations ofmetronidazole
(potency) and misonidazole (neurotoxicity) led to the
development of etanidazole and pimanidazole and subse-
quently of the more promising 'mixed function' compounds
containing both the sensitising nitro group and an aziridine
function, e.g. RSU 1069 and RB 6145. The heightened
cytotoxicity of nitroimidazoles in hypoxic, as compared with
oxic, cells has led to the development of a class of cytotoxic
chemicals which is activated by reduction in hypoxic
environments. In addition to nitroimidazoles, other classical
examples are mitomycin C and the indoloquinone E09. More
recently the benzotriazine di-N-oxides, notably SR4233, have
been discovered. The latter is unique in forming strand
breaks rather than DNA adducts post reduction. The one-
and two-electron reducing requirements for the various
activations and the associated enzymology is discussed, as is
the possibility of profiling these drugs to the bioreductive
phenotype of tumours. The overall approach is presented as
exploiting a common established defect of solid tumours.
The topic of 'therapeutic drug monitoring and dose
optimisation in oncology' is presented by Merrill Egorin. His
theme is the need to achieve optimal dosing of anti-cancer
drugs, which invariably possess low therapeutic indices, in
individual patients. A sound background to pharmacokinetic
and pharmacodynamic monitoring is provided, together with
a critique of three dosing strategies that could be adopted.
These are 'empiric dosing' (e.g. mg m2 as recommended for
phase II studies); 'adaptive dosing' (in which patient, disease
and drug characteristics are assessed in a regression model to
provide an individual dose recommendation against a
population database); and 'adaptive control with feedback
dosing' (which allows more closely for inter-patient phar-
macokinetic variability through refinements of the phar-
macokinetic model on an individual basis). Approaches to
the analysis of population pharmacokinetics and limited
sampling strategies are clearly presented and analysed. The
need for appropriate resources is stressed, as is the require-
ment for sensible cost-value benefit of such investigations.
The author also points to the need to initiate population
pharmacokinetic/pharmacodynamic modelling at the earliest
stages of the clinical evaluation of a new drug, since the basic
information required to undertake individual dose optimisa-
tion will be difficult, if not impossible, to obtain once the
drug is established.
Gilberto Schwartsmann reviews current strategies in anti-
cancer drug discovery within the EORTC. The rate of dis-
covery of clinically useful drugs is addressed briefly and the
point made that the major impact has been in the treatment
of relatively rare cancers (leukaemias, lymphomas, paediatric
tumours). This is attributed to the predominance of trans-
plantable mouse leukaemias, either as prescreens or as major
screening vehicles, in the tumour panels adopted for assess-
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It is also no doubt a consequence of the drug discovery
philosophy which has relied on large-throughput random
screening, rather than rational drug design. The inception
and evolution of the NCI compound-oriented screening pro-
gramme and its benefits and shortcomings are reviewed. Also
outlined is the current NCI screening programme, which is
disease oriented and embraces calibrated panels of human
tumour cell lines of given tissue types. The organisation of
the EORTC drug discovery initiative is discussed, indicating
the role played by the New Drug Development Office in
coordinating and integrating the efforts of the University of
Freiburg and the several collaborative EORTC preclinical
groups. The chapter concludes with a brief commentary on
the EORTC contributions to the development of several
promising new agents including taxol, taxotere, topotecan,
CPT-11, the anthrapyrazoles and suramin.
K.R. Harrap
Excited States and Free Radicals in Biology and Medicine.
Contributions from Flash Photolysis and Pulse Radiolysis
R.V. Bensasson, E.J. Land & T.G. Truscott, Oxford: Oxford
University Press, 1993, 431 pp. £50.00 Hardback. £23.50
Paperback.
This volume is essentially an expanded and extensively
revised second edition of the earlier work on this theme by
these authors, published by Pergamon in 1983 under a
similar title. Like the second edition of B. Halliwell and
J.M.C. Gutteridge's Free Radicals in Biology and Medicine
(Oxford University Press, 1989), it has many elements in
common with the earlier work, but there is plenty of new
material to justify its purchase. The authors' aim 'is to
introduce the reader to the expanding field of excited states
and free radicals in biology and medicine, a discipline at the
borderline of physics, chemistry, biology, pharmacology, and
medicine'. While Halliwell and Gutteridge aimed their book
mainly at biologists and clinicians and assumed little
knowledge of chemistry, Bensasson et al. 'concentrate on the
viewpoints of physical chemists'. As such the two volumes
are complementary not only from the viewpoint taken but
also in content.
The roles of free radicals and excited states in biological
processes are increasingly recognised to be extensive and
diverse. Any book attempting to cover this subject with
reasonable breadth while retaining depth must therefore be
selective. The 12 chapters of the new work still reflect the
research interests of the authors, but as these are quite broad
the book does provide a useful cross-section of the subject
matter. Particularly appreciated was the much expanded in-
troductory coverage, involving three chapters. These sum-
marized energy absorption processes for light and ionising
radiation, the nature and reactivity of radicals, and experi-
mental techniques used with pulsed radiation (and light)
sources. These three chapters, 100 pages in all compared with
19 pages of introduction in the 'first edition', included nine
pages discussing the theoretical treatment ofelectron-transfer
reactions. (The importance of this topic has recently been
recognised by the award of the Nobel Prize to R.A. Marcus
for his work in this area.) With the emphasis on the underly-
ing framework rather than on numerous experimental
examples, such 'mini-reviews' will prove more valuable for a
longer time than exhaustive lists of the latest research papers.
The next chapter discusses the production, detection and
reactions of 'activated forms of oxygen': singlet molecular
oxygen, superoxide, hydroxyl and peroxyl radicals, hydrogen
peroxide and (somewhat out ofplace, but very topical) nitric
oxide and nitrogen dioxide. Of the 40 pages, disappointingly,
only three are devoted to the 'biomedical properties of the
activated forms ofoxygen', and for fuller coverage the reader
will need to turn to Halliwell and Gutteridge, to H. Sies' two
volumes on Oxidative Stress (Academic Press, 1985, 1991), or
other of the numerous multiauthor works which have pro-
liferated in this area.
The chapter on 'pyrimidines, purines and nucleic acids' is
divided approximately equally into the chemistry of excited
states and radical species. The latter coverage provides a
useful update to the much more detailed discussion of this
topic in C. von Sonntag's The Chemical Basis of Radiation
Biology (Taylor & Francis, 1987). The chapter following, on
"amino acids, peptides and proteins', covers radical genera-
tion by light and other radicals, as well as a survey of
electron migration in proteins.
Three chapters particularly reflecting the research interests
of the authors follow. The (mainly excited state) chemistry of
carotenoids, including P-carotene and vitamin A, and their
pivotal roles in vision and photosynthesis are described. The
worrying increase in malignant melanoma more than justifies
a chapter devoted to the radical chemistry of melanogenesis
and melanoma, and the chemical basis for the clinical interest
in 4-hydroxyanisole as a route to exploit elevated tyrosinase
levels in melanoma. Pulse radiolysis and flash photolysis have
been ingeniously applied to unravel some of the complex
reaction pathways in melanogenesis. The following chapter is
devoted to photodermatology. Subjects covered include the
molecular mechanisms of skin damage by UV radiation, the
photochemistry and radical chemistry of drugs which have
photosensitising side-effects (such as phenothiazines and non-
steroidal anti-inflammatory drugs), photochemotherapy of
psoriasis, the basis for phototherapy as a treatment for
neonatal hyperbilirubinaemia and skin photosensitivity assoc-
iated with excess porphyrins.
The final three chapters are devoted to cancer: to
radiotherapy, chemotherapy and photodynamic therapy; of
the three, I found the last of most value. The chapter on
radiotherapy concentrates on radiosensitisation by oxygen
and electron-affinic chemicals, and is too brief to add much
new to von Sonntag's coverage or reviews by other authors.
A reference or two to the 'meta-analysis' of radiosensitiser
clinical trials, and oxygen measurements in tumours, as lead-
ins to the clinical experience would have been useful.
Radiosensitiser research led directly (the same compounds) to
the recent expansion in research into the selective chemo-
therapy of hypoxic tumour cells. The mechanisms underlying
the selectivity arise from fast, free radical reactions observ-
able directly by pulse radiolysis. It is therefore surprising that
the following chapter, on cancer chemotherapy, rather
neglects coverage of this important topic. The chapter con-
centrates instead on the reduction chemistry of anthracyclins
and mitomycin C, reflecting the detailed work by one of the
authors and his colleagues. The final chapter, on
photodynamic therapy (PDT), describes the primary photo-
processes in PDT, brief coverage of biological aspects and
current work towards new photosensitisers.
Specialists may well be disappointed with the coverage
extended to any individual theme, but it is unrealistic to find
in a single volume comprehensive coverage of all the con-
tributions of flash photolysis and pulse radiolysis to free
radical and excited state chemistry in biology and medicine.
The title itself implies a restriction in coverage: a dozen
volumes would be needed to cover in depth even the
chemical aspects of free radicals and excited states in biology
as a whole. The value of this book lies as much in the
extensive introductory chapters as in the coverage of the
selected examples. Every chapter is well constructed, with a
detailed contents list, interesting historical introductions and
concluding remarks. Each is well supported by extensive
referencing to the single bibliography comprising over 1,500
references, thankfully including full titles of articles. A short
appendix lists SI units and conversion factors, although I was
disappointed that radiation chemical yields were quoted
using obsolescent and non-SI G-values.
The book is good value for money, especially in paper-
back. It is an excellent complement to Halliwell and Gut-
teridge's coverage of free radicals in biology, and joins the
latter volume as an essential purchase for all workers in the
field.
P. Wardman